Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update Raises Full-year 2025 Total Revenues Guidance at the Midpoint; Reaffirms VOXZOGO Full-year Outlook 2025 Year-to-date Total Revenues Increased 11% Y/Y Led by More Than 20% Revenue Growth for PALYNZIQ and VOXZOGO BioMarin Focuses Commercial Portfolio; Pursuing Options to Divest ROCTAV ...

Core Insights - BioMarin Pharmaceutical Inc. raised its full-year 2025 total revenues guidance at the midpoint, reflecting strong demand for its therapies, particularly VOXZOGO and PALYNZIQ, which saw over 20% revenue growth [1][6][11] - The company reported a GAAP net loss of $31 million for Q3 2025, a significant decline from a net income of $106 million in Q3 2024, primarily due to a $221 million in-process research and development charge related to the acquisition of Inozyme Pharma [6][7][11] - BioMarin plans to divest ROCTAVIAN while continuing to evaluate out-licensing options for the gene therapy, aligning with its strategic focus on core business units [2][6][11] Financial Performance - Total revenues for Q3 2025 were $776 million, a 4% increase from $746 million in Q3 2024, driven by strong growth in VOXZOGO and PALYNZIQ [6][7] - Year-to-date total revenues increased by 11% to $2.347 billion compared to $2.107 billion in the same period last year [7][11] - Non-GAAP income for Q3 2025 decreased to $22 million from $178 million in Q3 2024, reflecting the impact of the IPR&D charge [6][7] Product Performance - VOXZOGO revenue for Q3 2025 was $218 million, up 15% year-over-year, with year-to-date revenue increasing 24% to $654 million [7][11] - PALYNZIQ achieved a 20% year-over-year growth in Q3 2025, with total enzyme therapies revenue growing 8% year-to-date [6][7] - The company is advancing its pipeline with several upcoming pivotal data readouts and potential product launches, including BMN 333 and BMN 401 [6][11] Strategic Focus - BioMarin is concentrating on its Enzyme Therapies and Skeletal Conditions business units, which are central to its growth strategy [2][6] - The company aims to expand VOXZOGO access in over 60 countries by 2027, with significant uptake in markets outside the U.S. [6][11] - The decision to divest ROCTAVIAN is part of a broader strategy to streamline its portfolio and focus on high-potential therapies [2][6]

Core Insights - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is recognized as a promising healthcare stock with significant upside potential, despite a recent price target reduction from $90 to $80 by Cantor Fitzgerald analyst Olivia Brayer [1] - J.P. Morgan analyst Jessica Fye maintains a Buy rating with a higher price target of $119, indicating strong confidence in the stock [2] - BMO Capital analyst Kostas Biliouris also supports a Buy rating with a price target of $115, highlighting the company's growth prospects following positive data presentations [3] Company Developments - BioMarin presented new data from 14 studies at the ASBMR Annual Meeting, showcasing the effectiveness of VOXZOGO® (vosoritide) in improving spinal morphology in young children [3] - The potential expansion of Palynziq into the adolescent market is identified as a key growth driver, which could enhance BioMarin's market share [4] - The company focuses on developing therapies for serious medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [4]

Core Insights - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is recognized as a promising biotech stock with significant growth potential [1] - The company reported total revenues of $825 million in fiscal Q2 2025, reflecting a 16% year-over-year increase and a 17% increase at constant currency [1] - GAAP diluted earnings per share (EPS) for the quarter reached $1.23 [1] Analyst Ratings - Christopher Raymond from Raymond James maintained a Buy rating on BioMarin and set a price target of $85.00 [2] - Wedbush's Yun Zhong also assigned a Buy rating for the stock, indicating positive sentiment [3] - H.C. Wainwright initiated coverage with a Hold rating and a price target of $60 [3] Product Pipeline - BioMarin develops therapies for serious and life-threatening medical conditions and rare diseases [4] - The company's product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [4]

Group 1: Company Overview - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company focused on providing solutions for serious and rare diseases and medical conditions, established in 1996 and headquartered in San Rafael, California [4] Group 2: Investment Interest - Hedge funds are showing strong interest in BioMarin, with Tealwood Asset Management Inc. increasing its holdings by 37.4% in the second quarter, acquiring an additional 5,874 shares for a total investment of $1,185,000 [1] Group 3: Future Outlook - The future of BioMarin is characterized by three key aspects: valuation, growth, and pipeline [2] - The company generates only 34% of its revenues from the U.S. healthcare system, which is currently under scrutiny for its high costs, indicating a relatively stable position for BioMarin [2] - BioMarin's pipeline includes significant candidates like Palynziq, which targets phenylketonuria (PKU) with an estimated global prevalence of 1 in 10,000 to 15,000 people, and is projected to have a compound annual growth rate (CAGR) of 9.38% from 2025 to 2030 [3]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] - A specific company is highlighted as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI technologies [3][7][8] Investment Opportunity - Wall Street is investing heavily in AI, but there is a looming energy crisis as AI technologies require vast amounts of electricity, comparable to the consumption of small cities [2][3] - The company in focus is positioned to benefit from the surge in demand for electricity driven by AI data centers, making it a potentially lucrative investment [3][8] Company Profile - The company owns significant nuclear energy infrastructure assets and is capable of executing large-scale engineering, procurement, and construction projects across various energy sectors [7][8] - It is noted for being debt-free and having a substantial cash reserve, which is nearly one-third of its market capitalization, providing financial stability and growth potential [8][10] Market Position - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend driven by tariffs [5][6] - It has an equity stake in another AI-related company, offering investors indirect exposure to multiple growth engines in the AI sector [9][10] Future Outlook - The article emphasizes the importance of investing in AI and energy infrastructure as the future of technology and economic growth, with a call to action for investors to seize the opportunity before significant price increases occur [11][12][13]

Core Insights - The biotechnology sector is increasingly recognized for its dynamic growth and potential for high returns, particularly in gene therapy and precision medicine [2][3] - Small- and mid-cap biotech companies are leading biopharmaceutical innovation, contributing to two-thirds of the industry's R&D pipeline [2] Company Highlights - **BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)** - Hedge fund holdings increased to 58, with Tealwood Asset Management expanding its position by 37.4%, now owning shares worth $1,185,000 [7] - The company's future is characterized by valuation, growth, and a strong pipeline, with only 34% of revenues derived from the U.S. healthcare market [8] - Key product Palynziq has a significant addressable market, with an estimated 9.38% CAGR from 2025 to 2030 for the drug [9][10] - **Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)** - Hedge fund holdings also at 58, with Wealth Enhancement Advisory Services reducing its stake by 64.5%, now holding shares worth $1,699,000 [11] - The company is expected to achieve over $1 billion in quarterly revenue by year-end and more than $1 billion in adjusted earnings in the upcoming year [12] - Alnylam's stock has outperformed the market by nearly 50% over the past year, driven by the successful launch of Amvuttra in TTR-CM [13][14]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BMRN over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking ...

Core Insights - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is recognized as a strong buy stock by Wall Street, with a price target set at $85.00 by Raymond James [1] - The company reported total revenues of $825 million in fiscal Q2 2025, reflecting a 16% year-over-year increase and a 17% increase at constant currency [2] - GAAP diluted earnings per share (EPS) for the quarter reached $1.23 [2] - BioMarin specializes in developing and commercializing therapies for serious and life-threatening medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [3]

Group 1 - BioMarin Pharmaceutical Inc. is considered one of the best affordable biotech stocks to invest in, with a Buy rating and a price target of $115.00 set by BMO Capital analyst Kostas Biliouris [1] - The potential expansion of Palynziq into the adolescent market is a key reason for the optimistic rating, as it may significantly increase market share [2] - Palynziq has shown strong efficacy and safety in adolescents, with improved tolerability and significant reductions in blood Phe levels compared to adults [2] Group 2 - BioMarin has a robust base business, and the potential of other products like Voxzogo supports a positive outlook for the stock [3] - The company develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [3]